ClinicalTrials.gg
Enrolling by invitationNCT07159087Updated Sep 8, 2025

The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients With Coronary ISR

An interventional study of Sirolimus Coated PTCA Balloon Catheter(Genoss® SCB) and Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO) in Coronary Arterial Disease (CAD), sponsored by Genoss Co., Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Genoss Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 4 months after the study started (first participant enrolled Feb 2025, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the safety and effectiveness of Genoss® SCB by comparing in-segment late lumen loss (LLL) to the control group (SeQuent® Please NEO) at 6 months in patients with coronary stent-in-stent restenosis (ISR) with a reference vessel diameter of 2.0-4.0 mm.

Read the detailed description

This pivotal study is a randomized controlled trial to compare with the control group (SeQuent® Please NEO), and will recruit 94 patients with in-stent restenosis (ISR) from 9 institutions. The test group (Genoss® SCB) and the control group (SeQuent® Please NEO) will be randomly assigned 1:1, and all patients will be followed up at 1, 6, and 12 months after the procedure. The primary endpoint is to evaluate in-segment late lumen loss by quantitative coronary angiography (QCA) by an independent assessor at 6 months after the procedure.

02

Conditions studied

  • Coronary Arterial Disease (CAD)

Keywords

  • In-stent Restenosis
03

In context

Lead sponsor

Genoss Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 19 years of age
  • Patients with in-stent restenosis who are candidates for percutaneous coronary intervention (PCI)
  • In cases corresponding to one of the following conditions: non-ST-segment elevation myocardial infarction (NSTEMI), stable angina, unstable angina, or silent myocardial ischemia
  • Women of * must agree to use at least one medically acceptable method of ** throughout the duration of the clinical trial
  • Subjects who voluntarily agree to participate and provide written
  • Subjects who are willing to comply with the requirements of the clinical trial protocol
  • Subjects who develop in-stent restenosis (ISR) ≥ 90 days after the index coronary stent implantation, with the restenosis classified as Mehran type I to III
  • Subjects with a maximum of two ISR lesions, with visually estimated significant coronary artery stenosis on quantitative coronary angiography analysis (QCA) meeting one of the following criteria:

    1. In asymptomatic patients: in-segment percent diameter stenosis (DS%) > 70% compared to the reference vessel diameter of the target vessel* (*Target vessel: the vessel containing the target lesion with the minimum lumen diameter.)
    2. In patients with angina symptoms or evidence of ischemia on non-invasive functional testing: DS% > 50%
  • On QCA, the ISR lesion(s) to be treated must have a lesion length \< 36 mm and the reference vessel diameter (RVD) of the target coronary artery must be between 2.0 mm and 4.0 mm.

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with ST-segment elevation myocardial infarction (STEMI) by .
  • Known or at screening to any of the following drugs or substances: Aspirin, Heparin, Clopidogrel, Prasugrel, Ticagrelor, Sirolimus, Paclitaxel, Delivery matrix (e.g., shellac, vitamin E-TPGS), Ticlopidine, Contrast agents (e.g., Iopromide) Note: Subjects with contrast media sensitivity may be enrolled if the reaction is manageable with and pheniramine; however, those with a known anaphylactic reaction are excluded.
  • Subjects who are scheduled for or require surgery within 1 year of the index procedure that would necessitate discontinuation of antiplatelet therapy.
  • Subjects with bleeding disorders, gastrointestinal ulcers, or any conditions that may increase the risk of bleeding, in which anticoagulation is contraindicated or limited.
  • Subjects with a (LVEF) \< 30% as assessed by echocardiography.
  • Severe renal failure (Creatinine > 2.0 mg/dL) that makes QCA inappropriate.
  • Subjects with cardiogenic shock.
  • Pregnant or breastfeeding women: Women of with a positive urine hCG (or serum β-hCG) test are excluded.
  • Subjects with an estimated of less than 1 year due to comorbid conditions.
  • Subjects with medical conditions such as significant psychiatric disorders that may interfere with trial participation or outcomes.
  • Subjects who, in the investigator's opinion, are inappropriate for this clinical trial or for whom participation poses increased risk.
  • Participation in another clinical trial currently or within 90 days prior to screening.
  • Any other condition deemed ethically or clinically inappropriate by the investigator to participate in the study: Specific reasons should be recorded in the Case Report Form (CRF).

[Exclusion Criteria Based on QCA and Pre-Dilatation Assessment of ISR Lesions]

  • ISR lesions located in graft vessels following coronary artery bypass grafting (CABG).
  • Presence of coronary stent fracture in the ISR lesion to be treated.
  • Target lesion with two or more stents implanted, i.e., all segments of the target lesion contain ≥2 layers of stents.
  • Presence of additional lesions proximal or distal to the target lesion (>2.0 mm RVD) with >50% stenosis.
  • Subjects requiring CABG based on any of the following:

    1. Lesions in the left main coronary artery.
    2. Triple-vessel coronary artery disease.
    3. Other conditions requiring CABG as determined by the investigator.
  • Subjects for whom pre-dilatation is not feasible or has failed, making application of the device difficult due to any of the following:

    1. Total occlusion of the target lesion.
    2. Evidence of thrombus not treatable with aspiration.
    3. Severe vessel tortuosity or calcification preventing access to the target site, as determined by the investigator.
    4. Other conditions deemed unsuitable for investigational device application by the investigator.
  • After lesion pre-dilatation, if any of the following are present:

    1. Need for atherectomy (rotational, orbital, or laser).
    2. Presence of flow-limiting dissection of NHLBI type C or higher requiring stent implantation.
    3. Residual stenosis* in the target lesion. (*Defined as in-segment DS > 30%)
    4. Fractional flow reserve (FFR) ≤ 0.8 (FFR measurement may be omitted at the discretion of the investigator.)
    5. TIMI flow \< 3
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Genoss® SCB

    Sirolimus Coated PTCA Balloon Catheter

    Device: Sirolimus Coated PTCA Balloon Catheter(Genoss® SCB)

  • Active comparator
    SeQuent® Please NEO

    Paclitaxel Coated PTCA Balloon Catheter

    Device: Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)

Interventions

  • DeviceSirolimus Coated PTCA Balloon Catheter(Genoss® SCB)

    Drug Coated Balloon

  • DevicePaclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)

    Drug Coated Balloon

06

What researchers measure

Primary outcomes

  1. In-segment late lumen loss after procedure

    In-segment refers to a portion including within 5 mm of each of the distal and proximal portions at the boundary of the inserted stent. Therefore, in-segment late lumen loss (LLL) is defined as the difference (mm) in the minimum lumen diameter (MLD) within the segment at 6 months from baseline.

    Time frame: at 6 months after procedure

Secondary outcomes

  1. In-stent late lumen loss after procedure

    In-stent refers to a portion between each of the distal and proximal portions. Therefore, in-stent late lumen loss (LLL) is defined as the difference (mm) in the minimum lumen diameter (MLD) within the segment at 6 months from baseline. This is assessed by an independent evaluator using quantitative coronary angiography analysis (QCA) imaging.

    Time frame: at 6 months after procedure

  2. Target Lesion Failure (TLF), %

    Target lesion failure is defined as a composite of cardiac death, target vessel-related myocardial infarction (TV-MI), and target lesion revascularization (TLR).

    Time frame: at 1 month, 6 months, and 12 months after procedure

  3. Patient-oriented composite endpoint (POCE), %

    POCE is defined as a composite of all-cause death, any myocardial infarction (MI), any revasularization or stroke.

    Time frame: at 1 month, 6 months, and 12 months after procedure

  4. Device success rate, %

    Device success rate is defined as successful delivery of the device to the target lesion during the procedure, normal inflation, deflation, and catheter withdrawal of the without balloon rupture.

    Time frame: Immediately after the procedure

  5. Procedural success rate, %

    The definition of procedural success includes the of device success, freedom adverse events in-hospital \[cardiovascular death, target lesion revascularization, peri-procedural myocardial infarction, any stroke, and BARC 3-5 bleeding\], and freedom from bail-out stenting.

    Time frame: up to 24 hours

  6. Binary restenosis rate, %

    defined as a in-segment diameter stenosis ≥ 50% at angiographic follow-up

    Time frame: at 6 months after procdure

  7. Cardiac Death, %

    Death caused by acute MI, Sudden cardiac, including unwitnessed, death, Death resulting from heart failure, Death caused by stroke, Death caused by cardiovascular procedures, Death resulting from cardiovascular haemorrhage (haemorrhage deriving from cardiac and/or vascular disease/injuries)

    Time frame: at 1 month, 6 months, and 12 months after procedure

  8. All-cause death, %

    Incidence rate of all-cause death including cardiac death.

    Time frame: at 1 month, 6 months, 12 months after procedure

  9. Target vessel myocardial infarction (TV-MI), %

    Incidence rate of target vessel myocardial infarction

    Time frame: at 1 month, 6 months, and 12 months after procedure

  10. Myocardial infarction (MI), %

    Incidence rate of all myocardial infarction

    Time frame: at 1 month, 6 months, and 12 months after procedure

  11. Ischemia-driven target lesion revascularization (ID-TLR), %

    Target lesion revascularization is defined as a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.

    Time frame: at 1 month, 6 months, and 12 months after procedure

  12. Ischemia-driven target vessel revascularization (ID-TVR), %

    Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.

    Time frame: at 1 month, 6 months, and 12 months after procedure

  13. Revascularization, %

    Revascularizations are defined according to the vessel/lesion treated and are identified as target or non-target, based on the initial site of the treatment.

    Time frame: at 1 month, 6 months, and 12 months after procedure

  14. Stent thrombosis

    Stent thrombosis will be assessed and classified according to the definitions established by the Academic Research Consortium-2 (ARC-2). Stent thrombus is classified based on how the diagnosis is confirmed. These classifications include definite, and probable stent thrombosis. Definite stent thrombosis Requires confirmation of stent thrombosis on angiography. Probable stent thrombosis Consider if there is active ischemia on electrocardiogram (EKG) or stress in the distribution of prior stent and absence of significant coronary lesion on angiography. Timing may be divided between acute, subacute, early, and late. When classified as early, or late: Early stent thrombosis occurs within one month of initial placement. Late stent thrombosis occurs between 1 and 12 months of initial placement. Early stent thrombosis is divided between acute or subacute: Acute thrombosis occurs within 24 hours of initial placement. Subacute thrombosis occurs between 24 hours to one month of initial place

    Time frame: at 1 month, 6 months, and 12 months after procedure

  15. Stroke, %

    Neuro-ARC definitions (according to ARC-2 criteria)

    Time frame: at 1 month, 6 months, and 12 months after procedure

  16. Major bleeding BARC type III to V, %

    Major bleeding according to the Bleeding Academic Research Consortium (BARC) scale includes BARC types 3 to 5. Type 3 bleeding encompasses significant bleeding, including overt bleeding with a hemoglobin drop, intracranial hemorrhage, and bleeding requiring surgery or vasoactive agents. Type 4 refers to bleeding related to coronary artery bypass grafting (CABG). Type 5 bleeding is fatal, either probable or definite. BARC Type 3: Significant Bleeding 3a: Overt bleeding plus a hemoglobin drop of 3-5 g/dL. 3b: Overt bleeding plus a hemoglobin drop of 3-5 g/dL, cardiac tamponade, surgical intervention required, or intravenous vasoactive agents used. 3c: Intracranial hemorrhage. BARC Type 5: Fatal Bleeding 5a: Probable fatal bleeding, no definitive cause of death but clinically suspected. 5b: Definite fatal bleeding, confirmed by imaging or autopsy.

    Time frame: at 1 month, 6 months, and 12 months after procedure

  17. Abrupt closure/ Sub abrupt closure, %

    ① Abrupt closure: Defined as a newly developed, significant reduction in blood flow within the target vessel (TIMI grade 0 or 1) that persists and requires an unplanned rescue strategy (including emergency surgery). This must be associated with mechanical dissection of the treated or manipulated vessel, coronary thrombosis, or severe spasm. ② Sub-abrupt closure: Defined as abrupt closure occurring after the index procedure (after the patient has left the procedure room) but before Visit 3 (4 weeks post-procedure).

    Time frame: at 1 months after procedure

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jul 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Sep 8, 2025
StartActual
Feb 19, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07159087
Lead sponsor
Genoss Co., Ltd.
Collaborators
Synex Consulting Ltd
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Feb 19, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Sep 8, 2025

Study contacts

In-ho Chea, MD
principal investigator · Cardiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion